JP2021112207A5 - - Google Patents

Download PDF

Info

Publication number
JP2021112207A5
JP2021112207A5 JP2021074862A JP2021074862A JP2021112207A5 JP 2021112207 A5 JP2021112207 A5 JP 2021112207A5 JP 2021074862 A JP2021074862 A JP 2021074862A JP 2021074862 A JP2021074862 A JP 2021074862A JP 2021112207 A5 JP2021112207 A5 JP 2021112207A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
pharmaceutical composition
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021074862A
Other languages
English (en)
Japanese (ja)
Other versions
JP7162097B2 (ja
JP2021112207A (ja
Filing date
Publication date
Priority claimed from JP2019565912A external-priority patent/JP6963036B2/ja
Application filed filed Critical
Publication of JP2021112207A publication Critical patent/JP2021112207A/ja
Publication of JP2021112207A5 publication Critical patent/JP2021112207A5/ja
Priority to JP2022146982A priority Critical patent/JP7458453B2/ja
Application granted granted Critical
Publication of JP7162097B2 publication Critical patent/JP7162097B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021074862A 2017-06-01 2021-04-27 Bet v 1に対するヒト抗体およびその使用方法 Active JP7162097B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022146982A JP7458453B2 (ja) 2017-06-01 2022-09-15 Bet v 1に対するヒト抗体およびその使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762513872P 2017-06-01 2017-06-01
US62/513,872 2017-06-01
US201762571696P 2017-10-12 2017-10-12
US62/571,696 2017-10-12
US201862662165P 2018-04-24 2018-04-24
US62/662,165 2018-04-24
JP2019565912A JP6963036B2 (ja) 2017-06-01 2018-05-31 Bet v 1に対するヒト抗体およびその使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019565912A Division JP6963036B2 (ja) 2017-06-01 2018-05-31 Bet v 1に対するヒト抗体およびその使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022146982A Division JP7458453B2 (ja) 2017-06-01 2022-09-15 Bet v 1に対するヒト抗体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2021112207A JP2021112207A (ja) 2021-08-05
JP2021112207A5 true JP2021112207A5 (https=) 2022-01-11
JP7162097B2 JP7162097B2 (ja) 2022-10-27

Family

ID=62705709

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019565912A Active JP6963036B2 (ja) 2017-06-01 2018-05-31 Bet v 1に対するヒト抗体およびその使用方法
JP2021074862A Active JP7162097B2 (ja) 2017-06-01 2021-04-27 Bet v 1に対するヒト抗体およびその使用方法
JP2022146982A Active JP7458453B2 (ja) 2017-06-01 2022-09-15 Bet v 1に対するヒト抗体およびその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019565912A Active JP6963036B2 (ja) 2017-06-01 2018-05-31 Bet v 1に対するヒト抗体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022146982A Active JP7458453B2 (ja) 2017-06-01 2022-09-15 Bet v 1に対するヒト抗体およびその使用方法

Country Status (17)

Country Link
US (3) US10793624B2 (https=)
EP (1) EP3630814A1 (https=)
JP (3) JP6963036B2 (https=)
KR (3) KR102878718B1 (https=)
CN (1) CN110997713B (https=)
AU (2) AU2018275657B2 (https=)
BR (1) BR112019025150B1 (https=)
CA (1) CA3063588A1 (https=)
CL (3) CL2019003508A1 (https=)
CO (1) CO2019013196A2 (https=)
IL (2) IL298034B2 (https=)
MX (2) MX2019014430A (https=)
MY (1) MY198270A (https=)
NZ (1) NZ759513A (https=)
PH (1) PH12019550238A1 (https=)
WO (1) WO2018222854A1 (https=)
ZA (1) ZA201907513B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107635527B (zh) 2015-03-10 2021-04-23 里珍纳龙药品有限公司 无菌刺穿系统和方法
KR102540409B1 (ko) 2017-05-05 2023-06-09 리제너론 파아마슈티컬스, 인크. 자동 주사기
IL298034B2 (en) 2017-06-01 2024-05-01 Regeneron Pharma Antibodies against BET V 1 and methods of using them
CA3177918A1 (en) * 2020-07-01 2022-01-06 Amanda ATANASIO Methods of treating allergy using anti-bet v 1 antibodies
CN113041271B (zh) * 2021-04-14 2022-12-27 浙江养生堂天然药物研究所有限公司 具有预防和抗过敏功效的组合物
USD1007676S1 (en) 2021-11-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Wearable autoinjector
CN118660719A (zh) * 2021-12-08 2024-09-17 艾吉尼克斯公司 用于过敏症疗法的组合
WO2024200854A1 (en) 2023-03-31 2024-10-03 Alk-Abelló A/S Allergen binding antibodies suitable for treating tree pollen allergies
WO2024251358A1 (en) 2023-06-07 2024-12-12 Mabylon Ag Anti-allergen antibodies and uses thereof
WO2024259313A1 (en) 2023-06-16 2024-12-19 Regeneron Pharamceuticals, Inc. Medical device packaging and related methods
US20250011403A1 (en) * 2023-07-03 2025-01-09 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode anti-sp17 antibodies and other sp17 binding proteins
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
TW202529831A (zh) 2023-10-02 2025-08-01 美商再生元醫藥公司 藥物遞輸裝置安全系統
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
US20250255994A1 (en) * 2023-11-29 2025-08-14 Medicovestor, Inc. Dimeric immunoconjugates for use in treating cancers and methods of use
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
US20250263471A1 (en) 2024-01-30 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-bet v 1 antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010194A2 (de) 1992-10-27 1994-05-11 Biomay Produktions- Und Handelsgesellschaft M.B.H. MOLEKÜLFRAGMENTE (PEPTIDE) DER HAUPTALLERGENE DER POLLEN VON BÄUMEN DER ORDNUNG $i(FAGALES)
WO1994014475A1 (en) 1992-12-21 1994-07-07 Tanox Biosystems, Inc. ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT
EP0619323A1 (en) 1993-04-09 1994-10-12 Schering-Plough Human monoclonal antibodies and processes and materials for making such antibodies
GB0002386D0 (en) 2000-02-02 2000-03-22 Novartis Nutrition Ag Therapeutic composition
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
ITMI20052517A1 (it) * 2005-12-29 2007-06-30 Lofarma Spa Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa
AT503297B1 (de) 2006-05-18 2007-09-15 Biomay Ag Allergen-spezifische antikörper
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
GB201002559D0 (en) 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
TW201920262A (zh) * 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素a之抗體及其用途
US10935554B2 (en) * 2013-08-23 2021-03-02 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)
IL298034B2 (en) 2017-06-01 2024-05-01 Regeneron Pharma Antibodies against BET V 1 and methods of using them
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAx抗-CD3抗體及其用途
CA3177918A1 (en) * 2020-07-01 2022-01-06 Amanda ATANASIO Methods of treating allergy using anti-bet v 1 antibodies

Similar Documents

Publication Publication Date Title
JP2021112207A5 (https=)
JP2020523004A5 (https=)
CN113597328B (zh) 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
CA2914203C (en) Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
RU2014148502A (ru) Человеческие антитела к fel d1 и способы их применения
JP2016521713A5 (https=)
JP2015523962A5 (https=)
JP2025172841A5 (https=)
WO2018081075A1 (en) Anti-il-33 antibodies and uses thereof
US20210148929A1 (en) Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
JPWO2020191346A5 (https=)
IL299207A (en) Methods of allergy treatment using anti-BET V 1 antibodies
RU2191601C1 (ru) Лекарственное средство и способ лечения эректильных дисфункций
Rolinck-Werninghaus et al. Anti-IgE therapy in allergic asthma
JPWO2022006305A5 (https=)
EP4204449A1 (en) Method of treating an allergy with allergen-specific monoclonal antibodies
Vogel et al. On the role of allergen-specific IgG subclasses for blocking human basophil activation
RU2023101304A (ru) Способы лечения аллергии и повышения эффективности аллергенспецифической иммунотерапии путем введения ингибитора ил-4р
NZ782911B2 (en) Human antibodies to bet v 1 and methods of use thereof
WO2025214333A1 (zh) 抗tslp抗体治疗与tslp相关的炎症疾病的方法
RU2789047C2 (ru) Способы лечения аллергии и повышения эффективности аллерген- специфической иммунотерапии путем введения ингибитора ил-4р
KR20130031136A (ko) 항-vegf 항체를 포함하는 자가면역질환 예방 및 치료용 조성물
RU2020140639A (ru) Способы лечения атопического дерматита посредством введения ингибитора ил-4r
JPWO2023130010A5 (https=)
WO2002026259A1 (en) A pharmaceutical composition for treating acids and its preparation